This was the stock's second consecutive day of losses.

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new ...

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday as strong demand for its cough-and-cold ...

Kenvue Inc. has announced the appointment of Amit Banati as chief financial officer, effective today. He will be responsible ...

Kenvue on Thursday forecast that its annual profit would be flat year-over-year as the consumer health firm anticipates a ...

Barclays analyst Lauren Lieberman maintained a Hold rating on Kenvue, Inc. (KVUE – Research Report) today and set a price target of $23.00. The company’s shares closed last Fr ...

Shares of Kenvue rose in early Thursday trading after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

Kenvue Inc. reported second-quarter earnings that surpassed analyst estimates, while updating its full-year 2025 guidance to account for tariffs and currency headwinds.

Shares of Kenvue Inc. KVUE slid 1.80% to $24.00 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 3.26% to 5,844.19 and the ...

Kenvue KVUE1.58%increase; green up pointing triangle, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial ...